Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients

Abstract

Background: We present our experience of therapeutic vaccination using dendritic cells (DC) pulsed with autologous tumor antigens in patients with advanced melanoma.

Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters

“…Monocyte‐derived DCs differentiated with a series of cytokines after leukopheresis were used in 49 of the 54 trials. Monocytes were mostly cultured with interleukin (IL)‐4 and granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) for differentiation to iDCs, followed by maturation with a combination of cytokines including tumor necrosis factor (TNF)‐α (Barbuto et al., 2004; Escobar et al., 2005; Nagayama et al., 2003; Trefzer et al., 2004, 2005; Wei et al., 2006); TNF‐α, IL‐1β, IL‐6, and prostaglandin E2 (PGE 2 ) (Hersey et al., 2008; Jonuleit et al., 2001; Kyte et al., 2006; Ridolfi et al., 2006; Schadendorf et al., 2006; Schuler‐Thurner et al., 2002; Tuettenberg et al., 2006; de Vries et al., 2003); TNF and soluble CD40L (Palucka et al., 2006); TNF‐α and poly(I:C) (Nakai et al., 2006); interferon (IFN)‐γ and ribomunyl (Lesimple et al., 2006); and calcium ionophore A23187, IL‐2 and IL‐12 (Bedrosian et al., 2003).…”

Human embryo immune escape mechanisms rediscovered by the tumor

“…survivin, with its anti-apoptotic properties, could be used as target therapy or in experimental vaccine trials (Zhang et al, 2006). A greater understanding of antigens shared by both embryonic and tumor tissues could help us to orient the immune response towards the tumor stem cell population, possibly leading to longer overall survival, as already seen in immunoresponsive patients (Ridolfi et al, 2006).…”

Surgery and adjuvant therapies in the treatment of stage IV melanoma: our experience in 84 patients

“…Subcutaneous interleukin-2 (IL-2; 3×10 6 IU) was administered from days3 to 7 of each treatment cycle [6].…”